Impact of Recent Clinical Data on Treatment for HER2+ MBC
Read More
CDK4/6 Inhibitors for Triple-Positive Breast Cancer
Read More
SOPHIA: Margetuximab + Chemotherapy for RR HER2+ MBC
Read More
DS-8201 and Tucatinib in HER2+ Metastatic Breast Cancer
Read More
Treatment Choice for Patient Relapsing With Brain Metastases
Read More
HER2CLIMB: Brain Metastases Data
Read More
Biomarker Data After Neoadjuvant Therapy for HER2+ Breast Cancer
Read More
HER2+ Early Stage Breast Cancer With Residual Invasive Disease
Read More
KAITLIN: T-DM1/Pertuzumab After Anthracycline-Based Adjuvant Therapy
Read More
TRAIN-2: Anthracyclines in HER2+ Breast Cancer
Read More
APHINITY and ExteNET Trials for Early-Stage Breast Cancer
Read More
HER2+ Early-Stage Breast Cancer
Read More
Guidelines and Approaches to HER2 Testing for Breast Cancer
Read More
Dr. Kaklamani on Triple Combination Treatment for Breast and Ovarian Cancer
December 31st 2014Virginia Kaklamani, MD, a professor of medicine in the Division of Hematology/Oncology at the University of Texas Health Sciences Center at San Antonio, discusses a recent clinical trial that looks at the combination of two chemotherapy drugs, carboplatin and eribulin, along with the PARP inhibitor E7449 for the treatment of breast and ovarian cancer.
Read More